The industrial manufacture of patient-derived organoids (PDOs) marks a significant advancement in biomedical research.
Image Credit: Gorodenkoff/Shutterstock.com
Three-dimensional (3D) Patient-Derived Organoids (PDOs) offer enhanced predictive capabilities and have the potential to serve as more clinically relevant models in applications traditionally reliant on two-dimensional (2D) cell lines, including high-throughput screening (HTS), genetic engineering and co-culture assays.
Despite these advantages, the widespread adoption of PDOs is currently hindered by challenges in producing them in sufficient quantities with the necessary quality and reproducibility.
Molecular Devices now offers a solution with its 3D Ready™ Organoids and the 3D Ready Organoid Expansion Service. Its proprietary bioreactor system is designed for the controlled, large-scale production of standardized PDOs.
These organoids are cultivated in a regulated environment that ensures the continuous delivery of essential nutrients and growth factors while preventing the accumulation of toxins that can compromise cell viability.
This innovative approach facilitates the large-scale production of assay-ready organoids that are viable and consistently sized across batches. 3D Ready Organoids are provided as cryopreserved vials, ensuring convenience for plating at the discretion of the user.
Download the full app note
Acknowledgments
Produce from materials originally authored by Carly Bunston, Harman Chaggar, Kim Luetchford and Giusy Tornillo from Molecular Devices.
About Molecular Devices UK Ltd 
Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications.
Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion.
To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.